- Home
- TPST vs ESLA Comparison
TPST vs ESLA Comparison
Compare TPST & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPST
- ESLA
- Stock Information
- Founded
- TPST 2011
- ESLA 2021
- Country
- TPST United States
- ESLA United States
- Employees
- TPST N/A
- ESLA N/A
- Industry
- TPST Biotechnology: Pharmaceutical Preparations
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TPST Health Care
- ESLA Health Care
- Exchange
- TPST Nasdaq
- ESLA Nasdaq
- Market Cap
- TPST 33.0M
- ESLA 35.5M
- IPO Year
- TPST N/A
- ESLA N/A
- Fundamental
- Price
- TPST $7.76
- ESLA $0.91
- Analyst Decision
- TPST Hold
- ESLA Strong Buy
- Analyst Count
- TPST 3
- ESLA 1
- Target Price
- TPST $30.00
- ESLA $16.00
- AVG Volume (30 Days)
- TPST 80.4K
- ESLA 18.0K
- Earning Date
- TPST 08-07-2025
- ESLA 08-20-2025
- Dividend Yield
- TPST N/A
- ESLA N/A
- EPS Growth
- TPST N/A
- ESLA N/A
- EPS
- TPST N/A
- ESLA N/A
- Revenue
- TPST N/A
- ESLA N/A
- Revenue This Year
- TPST N/A
- ESLA $101.09
- Revenue Next Year
- TPST N/A
- ESLA N/A
- P/E Ratio
- TPST N/A
- ESLA N/A
- Revenue Growth
- TPST N/A
- ESLA N/A
- 52 Week Low
- TPST $5.35
- ESLA $0.63
- 52 Week High
- TPST $28.34
- ESLA $3.23
- Technical
- Relative Strength Index (RSI)
- TPST 63.65
- ESLA 50.86
- Support Level
- TPST $6.11
- ESLA $0.83
- Resistance Level
- TPST $6.49
- ESLA $0.95
- Average True Range (ATR)
- TPST 0.35
- ESLA 0.07
- MACD
- TPST 0.03
- ESLA 0.01
- Stochastic Oscillator
- TPST 100.00
- ESLA 72.22
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.